Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:John_Simard
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
monoclonal antibody therapies
|
| gptkbp:foundedIn |
2005
|
| gptkbp:founder |
gptkb:John_Simard
|
| gptkbp:headquartersLocation |
gptkb:Austin,_Texas,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
XBiotech
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Bermekimab
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:researchArea |
oncology
inflammatory diseases |
| gptkbp:specializesIn |
immunotherapy
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:XBIT
|
| gptkbp:website |
https://www.xbiotech.com/
|
| gptkbp:bfsParent |
gptkb:Daniel_Vasella
|
| gptkbp:bfsLayer |
5
|